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Abstract: The course of schizophrenia is characterized by multiple relapses, incomplete 
remission of symptoms, enduring cognitive deficits, and social and occupational functional 
impairments. Nonadherence to antipsychotic medication is a major determinant of this poor 
outcome. Long-acting injectable antipsychotics were developed specifically to address the non-
adherence problem and are increasingly considered as an early treatment option, in an attempt 
to prevent accruing morbidity. This review focuses on paliperidone palmitate, the long-acting 
injectable (LAI) formulation of paliperidone. After considering the pharmacology of paliperi-
done palmitate, we review the randomized controlled trials, as well as pertinent observational, 
pragmatic studies for paliperidone once-monthly injections in schizophrenia. Finally, we review 
the recently introduced 3-monthly formulation of paliperidone palmitate. Taken together, the 
studies indicate that paliperidone palmitate (PP) has good efficacy compared with placebo and 
comparable with other antipsychotics including risperidone. The tolerability profile of PP is 
similar to that of risperidone, with the most important side effects being prolactin elevation, 
weight gain, and extrapyramidal symptoms. Advantages of PP include the extensive research 
database and clinical experience with paliperidone and its parent compound risperidone, the 
availability of different LAI formulations (once-monthly, 3-monthly, and perhaps even longer 
acting formulations in future), and the novel dose initiation procedure that provides rapid onset 
of action without the need for oral antipsychotic supplementation.
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Introduction
As a chronic and frequently debilitating brain disorder, schizophrenia is one of the 
leading contributors to the global disease burden. Despite its relatively low prevalence, 
the illness places an enormous emotional, health, social, and economic burden on 
patients, families, caregivers, and society.1 The course of schizophrenia is typically 
characterized by multiple relapses, incomplete remission of symptoms, enduring 
cognitive deficits, and social and occupational functional impairments.2 There is also 
evidence for emergent treatment refractoriness, with relapse events possibly being 
the critical factor.3 Antipsychotic treatment is effective in reducing acute psychotic 
symptoms and for preventing relapse by way of maintenance treatment. Despite the 
demonstrated effectiveness of antipsychotics, the need for indefinite treatment has 
recently been questioned, due to the side effect burden of these drugs and a study 
suggesting that patients who undergo dose reduction or discontinuation may do bet-
ter in the long term in terms of functional recovery.4 However, the effectiveness of 
maintenance antipsychotic treatment is extensively documented.5 Relapse rates are 
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very high when treatment is discontinued, even after a single 
episode of psychosis,6 and good adherence and persistence 
with antipsychotics is associated with reduced hospitaliza-
tion risk and lower total costs.7 Given the psychosocial and 
possible biological risks associated with discontinuation,8 
most clinicians continue to encourage indefinite maintenance 
treatment.
While it is established that schizophrenia is a neurode-
velopmental disorder,9 there is also evidence of illness 
progression after onset of the first psychotic episode. The 
illness trajectory has been proposed as having two phases. 
The first phase, comprising the early years, is when the illness 
is at its most aggressive, when relapses are most common, 
and where illness progression is most likely to occur. The 
second, chronic phase is when the illness has burnt itself out 
and patients stabilize insofar as acute psychotic episodes are 
less severe, although prominent deficits persist.10 Indeed, 
long-term data indicate that, even in patients who become 
relatively symptom free, psychosocial deficits are prominent 
and few achieve self-sufficiency and independent living.11
The importance of early identification, effective interven-
tion, and prevention of relapse in the early years of illness 
has been emphasized as the best strategy to minimize illness 
progression. First-episode patients are more responsive to 
acute treatment,12 although frequently the improvement is not 
maintained. This is consistent with a longitudinal study in 
patients with schizophrenia treated with oral antipsychotics 
where it was reported that, while 70% of participants met 
cross-sectional criteria for symptom remission at some time 
point in the study, only 23.6% maintained that status for 
6 months or longer.13 This suggests that, in the early stages of 
illness, the challenge is not so much in achieving a treatment 
response, but in maintaining that status. Perhaps the most 
important barrier to optimal outcomes is nonadherence to 
and poor persistence with treatment. About 80% of patients 
experience multiple relapses over the first 5 years of treat-
ment, and antipsychotic treatment discontinuation is by far 
the commonest predictor of relapse.14 The very high rates of 
discontinuation in studies such as the CATIE trial highlight 
the extent of the problem.15 While nonadherence and poor 
persistence is common in most chronic illnesses, the problem 
is compounded in schizophrenia where insight is impaired to 
the extent that there may be illness unawareness, symptom 
misattribution, and failure to recognize the need for treat-
ment.16 For these reasons, psychosocial and pharmacological 
interventions have focused on ways of improving adherence 
and persistence. Long-acting injectable antipsychotics (LAIs) 
were developed in the 1960s specifically to address the 
nonadherence problem, and the older, first-generation depot 
antipsychotics were used extensively in many countries as 
an effective way of ensuring maintenance treatment.17 How-
ever, these agents were typically reserved for the chronic 
stage of illness, for patients who had proven themselves to 
be nonadherent to medication and after multiple relapses. 
In keeping with modern day public health principles, it makes 
sense rather to address nonadherence and poor persistence 
from the outset, thereby preventing accruing morbidity.18 
Consequently, the use of LAIs as an early treatment option 
is increasingly considered. With the advent of the new gen-
eration oral antipsychotics two decades ago, it was hoped 
that these drugs would, by virtue of their more favorable 
tolerability profile, improve adherence and persistence. 
As a result, use of LAIs decreased. However, the newer oral 
antipsychotics failed to substantially improve adherence and 
reduce relapse rates.17,19 Subsequently, attention has again 
focused on developing LAI formulations, this time of the new 
generation antipsychotics. There are now LAI formulations 
for risperidone, olanzapine, aripiprazole, and paliperidone. 
The present selective review focuses specifically on paliperi-
done palmitate (PP), the LAI formulation of paliperidone. 
We conducted a Medline search using the search term “pali-
peridone palmitate”. References of the identified studies were 
cross-checked for additional relevant studies.
Pharmacology, mode of action, 
pharmacokinetics, and administration 
schedule
Paliperidone (9-hydroxyrisperidone) is the active metabolite 
of risperidone. Risperidone and paliperidone have similar 
receptor binding profiles, although there are some differ-
ences. While paliperidone antagonizes central dopamine 
D2 and serotonin 5-HT2A receptors as well as alpha1- and 
alpha 2-adrenergic receptors and H1 histaminergic receptors, 
the risperidone 5-HT2A/D2 binding ratio is significantly 
lower than that of paliperidone. Also, a hydroxyl group in 
the paliperidone molecule confers increased hydrophilic-
ity that contributes to differential effects on mitochondrial 
movement, protein expression, and phosphorylation.20 
Further, paliperidone may be less able to enter the brain 
due to its greater affinity for the transporter P-glycoprotein. 
Whether these pharmacological differences result in clini-
cal differences is not established. Renal excretion is the 
major route of paliperidone elimination. As such, PP is not 
recommended in patients with moderate or severe renal 
impairment.21 In vitro studies in human liver microsomes 
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Paliperidone palmitate in schizophrenia
metabolism of medicines metabolized by cytochrome P450 
isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, 
CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, in 
contrast to risperidone, no dose adjustment is required for 
patients with mild to moderate hepatic impairment, and being 
a CYP2D6 poor metabolizer may not be clinically relevant 
for paliperidone treatment.22
PP is the palmitate ester of paliperidone, provided as a 
nanocrystal suspension in an aqueous vehicle for parenteral 
administration. Due to its low water solubility, PP dissolves 
slowly after intramuscular injection before being hydrolyzed 
to paliperidone and absorbed into the systemic circulation. 
PP may be administered either as gluteal or as deltoid intra-
muscular injection. The original once-monthly injectable 
formulation of PP (PP-1M) was approved by the US Food 
and Drug Administration (FDA) in 2009 and is marketed 
as Invega Sustenna® (Janssen Pharmaceutica NV, Beerse, 
Belgium) in the United States and as Xeplion® (Janssen 
Pharmaceutica NV) in Europe. Mean C
max
 was higher after 
deltoid injection than after gluteal injection (except for the 
100 mg equivalent [eq.] dose), although the area under the 
curve extrapolated to infinity divided by weight (AUC
infinity
) 
for both injection sites was comparable at all doses. Median 
time to reach C
max
 ranged from 13 to 14 days after deltoid and 
13 to 17 days after gluteal injection across all doses.23
The recommended initiation of PP is with a dose of 150 mg 
on treatment day 1 and 100 mg 1 week later (day 8), both admin-
istered in the deltoid muscle in order to attain rapid therapeutic 
concentrations. The third dose should be administered 1 month 
after the second initiation dose. The recommended monthly 
maintenance dose is 75 mg, and the recommended dose range 
is 25–150 mg. Patients who are overweight or obese may 
require doses in the upper range. Monthly maintenance doses 
can be administered in either the deltoid or gluteal muscle.21
Randomized, controlled trials vs 
placebo for acute, symptomatic 
schizophrenia
Efficacy and safety of flexible doses of PP-1M was demon-
strated in four short-term double-blind, placebo-controlled, 
randomized, controlled trials (RCTs) (Table 1). In a Phase 2b 
study over 9 weeks, acutely symptomatic participants (n=197) 
received gluteal injections of PP (fixed doses of 50 or 
100 mg eq.) or placebo on days 1, 8, and 36. Positive and 
Negative Syndrome Scale (PANSS) total scores improved 
significantly at end point for both doses (P0.01) vs 
placebo. Fewer PP-treated (2%) vs placebo-treated (10%) 
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Paliperidone palmitate in schizophrenia
events. PP-treated patients experienced more parkinsonism 
than placebo.24 A 13-week RCT evaluated the efficacy, safety, 
and tolerability of fixed doses of 25, 50, and 100 mg eq. 
PP-1M vs placebo was given as gluteal injections on days 1 
and 8, then every 4 weeks (days 36 and 64) in patients with 
schizophrenia (n=518). All PP dose groups showed significant 
improvement vs placebo in the PANSS total score (P0.001) 
and Clinical Global Impression (CGI) Severity scores 
(P0.006), but not in the Personal and Social Performance 
(PSP) scale score. The incidence of treatment-emergent 
adverse events was similar between groups, as were changes 
in parkinsonism and body mass index.25 Another 13-week 
RCT evaluated the efficacy and safety of PP-1M (50, 100, 
or 150 mg eq.) vs placebo administered as monthly gluteal 
injections after two initial doses given 1 week apart in acutely 
symptomatic patients with schizophrenia (n=388). As only 30 
participants were randomized to the 150 mg eq. dose group, 
definitive conclusions could not be drawn from the results 
of that group. PANSS total change scores were significantly 
better than placebo only for the 100 mg eq. group (P=0.02). 
Both the PP 50 (P=0.004) and 100 mg eq. (P0.001) groups 
showed significant improvement in the PSP score vs placebo. 
Adverse events reported more frequently in the PP groups 
than with placebo were headache, vomiting, extremity pain, 
and injection site pain.26 Another 13-week RCT assessed the 
efficacy and the safety of a dosing regimen for PP-1M that 
was revised from earlier studies for patients with acutely 
exacerbated schizophrenia (n=652). Patients received an 
injection of PP 150 mg eq. or placebo in the deltoid muscle 
on day 1 and the assigned fixed dose (PP 25, 100, or 150 mg 
eq.) or placebo in the deltoid or gluteal on day 8 and then 
once monthly. Target plasma levels were achieved by day 8 
in the PP groups. PANSS total scores improved significantly 
(P0.03) in all the PP dose groups vs placebo. Common 
treatment-emergent adverse events that occurred more fre-
quently in the PP group vs the placebo group were injection 
site pain (7.6% vs 3.7%), dizziness (2.5% vs 1.2%), sedation 
(2.3% vs 0.6%), pain in the extremity (1.6% vs 0.0%), and 
myalgia (1.0% vs 0.0%).27 A post hoc analysis in a subgroup 
(n=312) of markedly to severely ill patients in the abovemen-
tioned study found that compared with placebo, PP improved 
psychotic symptoms by day 4, and after subsequent injections, 
dose-dependent improvements persisted.28
Randomized, controlled trial vs 
placebo for maintenance treatment
Efficacy of PP-1M vs placebo in relapse prevention was 
assessed in a complex study design. Patients with a PANSS 
total score 120 were transitioned from previous anti-
psychotics to PP during a 9-week, open-label phase. Two 
intramuscular injections of 50 mg eq. PP were given 1 week 
apart, followed by flexibly dosed monthly injections (25, 50, 
or 100 mg eq.). Stable patients (PANSS total score 75) 
then entered a 24-week maintenance phase, following which 
they were randomized to either continue PP at the stabilized 
dose or begin placebo in the double-blind phase. Time-to-
relapse, the primary end point, was significantly delayed for 
PP (P0.0001) for the interim (n=312) and final analysis 
(n=408). Across the phases, mean weight increased by 1.9 kg 
for PP while it remained unchanged for placebo patients. The 
incidence of glucose-related adverse events was low (4%). 
Injection site tolerability was comparable between groups.29 
In a 1-year open-label extension to this study, the safety and 
tolerability of PP were assessed. Patients received gluteal 
injections of PP-1M starting at 50 mg eq., followed by flexible 
dosing of 25, 50, 75, or 100 mg eq. Two-hundred and eighty 
eight of the 388 enrolled patients completed the open-label 
extension. The most frequently reported adverse events were 
insomnia (7%), worsening of schizophrenia, nasopharyngi-
tis, headache, and weight increase (6% each). Potentially, 
prolactin-related adverse events occurred in 3% of patients, 
who were mostly women. Emergent extrapyramidal symp-
toms (EPS) were reported in 6% of patients. At the end point, 
investigator-rated redness at the injection site was observed 
in 4% of patients and injection site pain was rated by 
investigators as absent in 82%–87% of patients.30
A RCT evaluated the effect of PP-1M on the PSP scale 
in patients with schizoaffective disorder experiencing an 
acute exacerbation of psychotic and mood symptoms. Sub-
jects were treated with PP-1M either as monotherapy or in 
combination with antidepressants or mood stabilizers during 
a 25-week open-label phase (n=667), and stabilized subjects 
(n=334) were randomly assigned to PP-1M or placebo in a 
15-month double-blind relapse-prevention phase. Improve-
ments in all PSP domains were observed during the open-
label phase and were maintained during the double-blind 
phase with PP but not with placebo.31
Comparative randomized, 
controlled trials
PP-1M vs risperidone long-acting 
injectable
A 53-week, Phase III RCT was designed to assess the 
noninferiority of PP-1M to risperidone long-acting inject-
able (RLAI) in 747 patients with schizophrenia. Acutely 
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injections of either PP 50 mg eq. on days 1 and 8, followed 
by flexible dosing (25–100 mg eq.) once-monthly, or RLAI 
2-weekly, 25 mg on days 8 and 22 followed by flexible 
dosing (25–50 mg) starting from day 36, with oral risperi-
done supplementation. Mean (SD) change from baseline 
to end point in PANSS total score was -11.6 (21.22) for 
PP and -14.4 (19.76) for RLAI, and least-squares means 
difference was -2.6 (95% CI: -5.84, 0.61). PP’s failure to 
demonstrate comparable efficacy to RLAI was attributed to 
the suboptimal initiation dosing regimen which resulted in 
lower median plasma levels of the active moiety in PP-treated 
patients. Tolerability profiles of both treatments were com-
parable to previous studies.32
Another RCT, also designed to assess noninferiority of 
PP vs RLAI, was conducted in 1,220 patients with schizo-
phrenia over 13 weeks. The dosing regimen for the PP arm 
was as follows: deltoid injections on day 1 (150 mg eq.), 
day 8 (100 mg eq.), and flexible dosing as deltoid or gluteal 
injections on day 36 (50 mg eq. or 100 mg eq.) and day 64 
(50 mg eq., 100 mg eq., or 150 mg eq.). For the RLAI arm, 
patients received gluteal injections on days 8 and 22 (25 mg), 
days 36, 50 (25 or 37.5 mg), and days 64, 78 (25, 37.5, or 
50 mg), and oral supplementation with risperidone on days 
1 to 28. Mean (SD) PANSS total score change from baseline 
to end point decreased similarly in both groups: PP (-18.6 
[15.45]) and RLAI (-17.9 [14.24]). PP treatment was nonin-
ferior to RLAI (point estimate [95% CI]: 0.4 [-1.62, 2.38]). 
The tolerability and safety of PP was generally similar to that 
of RLAI.33 This dosing regimen subsequently became the rec-
ommended initiation dosing procedure for PP-1M. In a post 
hoc subgroup analysis in markedly to severely ill subjects 
(n=292) from this study, PANSS total scores improved sig-
nificantly in both arms, starting from day 4 through to end 
point;34 and in another post hoc, subgroup analysis from this 
study, no significant differences in the mean weight change, 
most metabolic parameters, or mean efficacy measures were 
observed over the 13 weeks of treatment.35
An open-label, rater-blinded, RCT evaluated noninferi-
ority of PP-1M to 2-weekly RLAI in 452 Chinese patients 
with acute schizophrenia. PP-treated patients received deltoid 
injections on day 1 (150 mg eq.) and day 8 (100 mg eq.), 
and then once-monthly deltoid or gluteal injections, flex-
ibly dosed (50, 100, or 150 mg eq.). RLAI-treated patients 
received 2-weekly gluteal injections, flexibly dosed (25, 
37.5, or 50 mg), and oral risperidone supplementation at 
initiation and with RLAI dose increases. Mean (SD) change 
from baseline to end point in PANSS total scores was -23.6 
(16.28) for the PP group and -26.9 (15.43) for RLAI group. 
PP was noninferior to RLAI (least-squares mean difference 
[95% CI]: -2.3 [-5.20, 0.63]). The incidence of treatment-
emergent adverse events was similar between the two groups. 
The most common adverse events were akathisia, tremor, 
and insomnia.36
A 6-month, open-label RCT compared the effects of 
RLAI and PP-1M on social functioning in a small sample of 
patients with schizophrenia (n=30). The PP-treated patients 
showed a greater degree of total social functioning, inde-
pendent life competence, and performance as compared to 
the RLAI group.37 In the same sample, effects of PP-1M and 
RLAI on cognitive functions were compared. The results 
suggested that PP might improve attention and processing 
speed more than RLAI.38 A pragmatic, randomized, open-
label, flexible dose study compared PP-1M (n=226) with 
oral antipsychotics (n=218) over 15 months in patients with 
schizophrenia and a history of contact with the criminal 
justice system. The mean cumulative function of treatment 
failure events and institutionalizations differed significantly 
in favor of PP compared with oral antipsychotics (P=0.007 
and P=0.005, respectively).39 To assess patient satisfaction 
with switching from oral antipsychotics to a long-acting 
injectable antipsychotic formulation, a 21-week, open-label 
RCT was conducted in 154 patients with schizophrenia 
dissatisfied with current oral atypical antipsychotics. Par-
ticipants were randomized to either immediate or delayed 
switching to PP-1M. Medication satisfaction improved 
significantly in both groups, with comparable efficacy and 
tolerability (Table 2).40
PP-1M vs aripiprazole once-monthly 
400 mg
A randomized, noninferior, open-label, rater-blinded, 
head-to-head comparison of PP-1M and aripiprazole once-
monthly 400 mg (AOM 400) was conducted over 28 weeks 
in 295 patients with schizophrenia, with the Heinrichs–
Carpenter Quality-of-Life Scale (QLS) score as the primary 
outcome. Sixty-eight percent of AOM 400 and 57% of PP 
patients completed 28 weeks of treatment. AOM-treated 
patients showed significantly greater improvements in the 
QLS total score (4.67 [95% CI: 0.32, 9.02], P=0.04). There 
were also significantly greater improvements in CGI Severity 
scale and the Investigator’s Assessment Questionnaire for 
AOM 400 vs PP. Common treatment-emergent adverse 
events in the treatment continuation phase were more fre-
quent with PP vs AOM 400.41
PP-1M vs haloperidol decanoate
A double-blind RCT was conducted in 311 patients with 
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Paliperidone palmitate in schizophrenia
assessed to be at risk of relapse, for up to 24 months, to com-
pare the effectiveness of PP-1M vs haloperidol decanoate. 
The primary outcome measure was efficacy failure, defined 
as a psychiatric hospitalization, a need for crisis stabiliza-
tion, increase in frequency of outpatient visits, a clinician’s 
decision that oral antipsychotic could not be discontinued 
within 8 weeks after starting the LAIs, or a clinician’s deci-
sion to discontinue due to inadequate therapeutic benefit. 
There was no statistically significant difference in the rate 
of efficacy failure for PP-1M compared with haloperidol 
decanoate (adjusted hazard ratio: 0.98; 95% CI: 0.65, 1.47). 
Forty-nine (33.8%) patients in the PP group and 47 (32.4%) 
in the haloperidol decanoate group experienced efficacy 
failure. Overall, participants in the PP group gained weight 
and those in the haloperidol decanoate group lost weight. 
The PP-treated patients had significantly higher maximum 
mean levels of serum prolactin while haloperidol decanoate-
treated patients had significantly greater increases in global 
ratings of akathisia.42 In a relative cost-effectiveness study in 
the same cohort, mixed-model analysis showed that PP-1M 
was associated with 0.0297 greater quality-adjusted life years 
over 18 months (P=0.03), but with higher average costs for 
inpatient and outpatient services and medication compared 
with haloperidol decanoate (P0.001).43
PP-1M vs oral antipsychotics in recent-
onset schizophrenia
An RCT assessed the efficacy of PP-1M vs physician’s choice 
of oral antipsychotics for relapse prevention in patients with 
a recent diagnosis of schizophrenia (within 5 years). Patients 
who met predefined response criteria were entered into the 
24-month rater-blinded treatment phase. Time to relapse was 
significantly longer in the PP-1M (n=352) compared with 
the oral antipsychotics arm (n=363), with 85% relapse-free 
survival at 469 days for PP-1M patients vs 249 days for oral 
antipsychotics patients (P=0.02). There were significantly 
fewer relapses in the PP-1M group (14.8% vs 20.9%; P=0.03), 
representing a 29.4% relative risk reduction. Improvements 
in functionality were comparable between treatment arms.44 
In a pooled analysis of two RCTs (PP-1M and PP-3M), predic-
tors of caregiver burden were evaluated (n=1,498 caregivers). 
Caregiver burden was significantly improved for patients on 
prior oral antipsychotics after switching to PP.45
Observational studies and 
uncontrolled pragmatic trials 
with paliperidone once-monthly
In a naturalistic study conducted over 1 year to determine the 
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initiation as an outpatient (P=0.001), being switched from 
risperidone (P=0.03), and correct initiation dosing (P=0.02) 
were significantly associated with a lower likelihood of 
discontinuation.46 Another naturalistic study explored 
efficacy, safety, and tolerability of PP-1M initiated shortly 
after hospital admission in 367 patients hospitalized for 
an exacerbation of schizophrenia, over 6 weeks. Signifi-
cant improvements were observed in psychotic symptoms 
(P0.0001) and PSP scores (P0.0001), and the treatment 
was well tolerated.47
A study comparing real-world health care costs and 
resource utilization between patients with schizophrenia 
treated with PP-1M and oral atypical antipsychotics found 
that patients treated with PP had lower inpatient costs and 
admission rates, although total health care costs were not 
significantly different.48
A retrospective mirror-image observational study 
assessed the effects of PP-1M on acute inpatient hospitaliza-
tion rates in 66 patients with schizophrenia who had received 
PP-1M for at least 1 year. The mean number of acute admis-
sions fell from 0.86 in the year before PP initiation to 0.23 
in the following year (P=0.001).49
An observational, claims-based study examined the 
frequency and duration of concurrent oral prescriptions in 
340 patients receiving LAI formulations of antipsychotics 
(first and second generation) with a recent history of nonad-
herence and hospitalization for schizophrenia. The lowest rate 
of concurrent oral prescribing (58.8%) was found with PP, 
whereas the highest rate was with RLAI (88.9%).50
A single-arm, multicenter, open-label, 6-month study in 
patients with schizophrenia assessed the tolerability, safety, 
and efficacy of flexible doses of PP-1M in a subset of non-
acute but symptomatic patients previously unsuccessfully 
treated with oral antipsychotic agents (n=593). PANSS total 
scores decreased from 71.5 (14.6) at baseline to 59.7 (18.1) 
at end point (P0.0001). PSP scores improved significantly 
from baseline to end point (P0.0001).51 In the same study, 
but assessing only patients who switched to PP-1M after 
unsuccessful treatment with RLAI or conventional depot 
antipsychotics (n=231), significant reductions in PANSS total 
scores were observed after switching (P=0.01).52 A third sub-
set analysis of the same study was conducted in patients with 
acute symptoms of schizophrenia following switching from 
previously unsuccessful treatment with oral antipsychotics 
who were switched to PP-1M (n=212). Significant improve-
ments in PANSS total score were observed from day 8 
onwards (P0.0001). PP was also associated with significant 
improvements in secondary measures of symptom severity, 
subjective well-being, medication satisfaction, illness-related 
disorders of activity and participation, and patient functioning 
(P0.0001). PP was generally well tolerated, with significant 
reductions in Extrapyramidal Symptom Rating Scale total 
score (P0.0001).53 A 25-week, open-label study evaluated 
safety and efficacy of PP-1M in 353 Chinese patients with 
schizophrenia. PANSS total scores improved significantly 
(P0.0001), as did PSP scores (P0.0001). Most frequently 
reported emergent adverse events were extrapyramidal dis-
order (15.3%), akathisia (10.5%), blood prolactin increase 
(8.8%), and insomnia (5.4%). Eight deaths were reported, 
including four completed suicides.54
A retrospective cohort study compared data on rehos-
pitalization patterns and associated institutional costs after 
inpatient treatment with PP-1M or oral antipsychotic therapy. 
In the first 12 months after hospital discharge, the risk of 
rehospitalization and emergency room use was significantly 
lower in the PP-1M cohort than in the oral antipsychotic 
cohort (P0.0001), and institutional costs during the first 
6 months after discharge were significantly lower in the 
PP-1M cohort (P0.0001).55
A prospective observational study over 3 months assessed 
the effect of switching from RLAI to PP-1M on sexual func-
tion and prolactin levels in a small sample (n=11) of patients 
with psychosis who developed hyperprolactinemia on RLAI 
and who were then switched to PP. There was a significant 
decrease in serum prolactin levels (P=0.04) and a fourfold 
reduction in clinically significant sexual dysfunction.56
A retrospective, observational cohort study using patient 
claims data compared effectiveness evidence for PP-1M vs 
oral atypical antipsychotics. Emergency room visits and 
hospitalization rates were lower in PP-1M patients, although 
hospitalizations did not achieve statistical significance.57
In an observational study, 200 consecutive patients 
prescribed PP in normal practice were followed up. After 
1 year, 65% of patients were still receiving PP. The number 
of admissions to hospital in the year following PP initiation 
was 0.49/patient compared with 0.69/patient/year for the 
3 years before initiation (P=0.0001). The median number of 
bed days for the 3 years before PP initiation was 21.50/year 
and in the year following PP initiation, it was 0.58
In a noninterventional, observational study of consecu-
tive patients treated with PP-1M (n=300), 38.7% completed 
2 years of continuous treatment and a further 7.6% patients 
discontinued PP but restarted after 2 months. Prior treat-
ment with risperidone reduced the risk of discontinuation 
by 39% (P=0.004) and having treatment initiated as an out-
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increased by 63% when the reason for prescribing PP was 
poor tolerability of the prior treatment (P=0.028).59
A part-prospective mirror-image study examined out-
comes 2 years before starting PP-1M and 2 years after 
(n=225). At study end point, 41.8% of patients were still 
receiving PP-1M. The number of admissions fell from 1.80 
in the 2 years before starting PP-1M to 0.81 in 2 years fol-
lowing initiation or discharge (P0.001). Total bed days 
were reduced from 79.6 in the 2 years before to 46.2 in the 
2 years after initiation or discharge (P0.001).60
The relapse risk following a switch from RLAI to PP-1M 
(n=188) vs a switch from RLAI to oral antipsychotics 
(n=131) was examined using information from a Medicaid 
database. Patients who switched from RLAI to PP had fewer 
events (hospitalization or emergency room visit) (26 vs 32), 
longer time to an event (mean 70 vs 47 days), and lower risk 
of relapse (P=0.02) compared with those who switched from 
RLAI to oral antipsychotics.61
A naturalistic cohort of all identifiable patients who 
initiated PP-1M in a specific region in the United Kingdom 
(n=179) was assessed. Sixty percent of patients continued 
PP-1M beyond 12 months. Schizophrenia diagnosis, fewer 
inpatient days after initiation, dose adjustment up or down, 
and a higher maintenance dose were associated with treat-
ment continuation.62
In an 18-month, open-label, noncomparative study 
from the Asia-Pacific region, patients with recent-onset 
schizophrenia (5 years) who were unsatisfactorily treated 
with previous oral antipsychotics (n=521) were treated with 
flexible doses of PP-1M. PANSS total scores improved 
significantly (P0.0001). There were greater improvements 
among patients with more severe symptoms. In a mirror 
analyses subset (n=474), PP significantly reduced mean 
number of hospitalization days/person/year as well as per-
centage of patients requiring hospitalization in past 12 months 
(P0.0001). Adverse events (15%) were EPS (31.3%), 
injection site pain (18.6%), and insomnia (15.2%).63
A retrospective claims-based analysis of Medicaid patients 
with schizophrenia compared all-cause health care utiliza-
tion and costs between patients treated with PP-1M (n=722) 
vs atypical oral antipsychotics (n=722). Over 12 months, 
PP-1M patients were less likely to discontinue treatment 
(30.6% vs 39.5%, P0.001) or switch to a new therapy 
(21.6% vs 27.7%, P=0.007) and had fewer inpatient visits 
(5.0 vs 7.9, P0.001), lower mean hospitalization days (15.0 
vs 27.7 days, P0.001), and inpatient costs (US$5,060 vs 
US$10,880, P=0.001). Pharmacy costs were significantly 
higher in the PP-1M cohort (P0.001), although total costs 
were not significantly different (P=0.853).64 Another study 
in patients recently diagnosed with schizophrenia compared 
adherence, health care resource utilization, and Medicaid 
spending between schizophrenia patients treated with PP-1M 
(n=2,053) vs those treated with oral atypical antipsychotics 
(n=22,247). Patients treated with PP-1M had better adherence 
(P0.001) and required less use of concomitant psychiatric 
medications. Lower medical costs associated with PP-1M 
outweighed the higher pharmacy costs, with similar total 
health care costs across the groups.65
An international, multicenter, retrospective chart review 
of medical records of adult patients who were newly diag-
nosed (1 year) with schizophrenia and who had received 
continuous treatment with PP-1M for 12 months in natural-
istic clinical settings (n=84) was undertaken. Of the patients, 
79.2% had 20% improvement and 47.2% had a 50% 
improvement in PANSS total scores. PSP scores improved 
significantly in 53.3%. Most adverse drug reactions were 
mild or moderate in severity (Table 3).66
Three-monthly paliperidone 
palmitate
In 2015, a new formulation, 3-monthly injection of prolonged 
release suspension of PP (PP-3M), was approved for the 
maintenance treatment of schizophrenia in adult patients 
by the European Medicines Agency (Trevicta®, Janssen 
Pharmaceutica NV), following earlier approval in the United 
States by the Food and Drug Administration (Invega Trinza®, 
Janssen Pharmaceutica NV). Pharmacokinetic studies sup-
port the feasibility of administering PP on a 3-monthly basis, 
subsequent to stabilization of treatment with the administra-
tion of four once-monthly injections of PP-1M, at doses 3.5 
times higher than the last dose of PP-1M. The dose range 
for PP-3M is 175, 300, 450, and 525 mg eq.67
A relapse-prevention RCT compared PP-3M to placebo 
in 506 patients with schizophrenia. The trial comprised four 
phases, namely a 3-week screening phase; a 17-week, flexible-
dose, open-label transition phase; a 12-week open-label main-
tenance phase; and an open-ended double-blind phase. Patients 
received once-monthly doses of PP-1M (50, 75, 100, or 150 mg 
eq.) during the transition phase, followed by a single dose of 
PP-3M (at 3.5 times the stabilized dose of PP-1M) during the 
maintenance phase. Stable patients were then randomized to 
receive either a fixed dose of PP-3M (175, 263, 350, or 525 mg 
eq.) or placebo once every 3 months during the double-blind 
phase. In the preplanned interim analysis, time to relapse was 
significantly longer in the PP-3M group vs the placebo group 






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Paliperidone palmitate in schizophrenia
domain score reductions were greater in PP-3M than placebo 
(P=0.01). In the double-blind phase, the most frequently 
reported adverse events in the PP-3M vs placebo groups were 
headache (9% vs 4%), weight gain (9% vs 3%), nasopharyn-
gitis (6% vs 1%), and akathisia (4% vs 1%).68
A double-blind RCT was designed to test the noninferi-
ority of PP-3M formulation to PP-1M in 1,016 patients with 
schizophrenia who were previously stabilized on PP-1M. 
After screening and a 17-week, flexible-dosed, open-label 
phase, clinically stable patients were randomized to PP-3M 
(fixed-dose, 175, 263, 350, or 525 mg eq. deltoid/gluteal) or 
PP-1M (fixed-dose, 50, 75, 100, or 150 mg eq. deltoid/gluteal) 
for a 48-week double-blind phase. PP-3M was noninferior to 
PP-1M insofar as relapse rates were similar in both groups 
(8% vs 9%), as were PANSS total score changes and PSP 
score changes. There were no clinically relevant differences in 
pharmacokinetic exposure between PP-3M and PP-1M. Both 
groups had similar tolerability profiles with weight gain as the 
most common treatment-emergent adverse event.69 A post 
hoc analysis assessed the rates of symptomatic and functional 
remission achieved following PP-3M vs PP-1M treatment in 
the same sample. In the PP-3M group, 50.3% achieved symp-
tomatic remission vs 50.8% in the PP-1M group. Functional 
remission was achieved in 42.5% in the PP-3M group and 
43.9% in the PP-1M group.70 Another post hoc analysis of a 
subset of patients from the same study assessed 510 East Asian 
participants. Again, the percentage of patients who relapsed 
was similar for PP-3M (10.2%) and PP-1M (11.8%), as was 
symptom reduction.71 Results from the abovementioned piv-
otal Phase III RCTs indicate that PP-3M was efficacious and 
generally well tolerated. The most frequently reported adverse 
events were anxiety, insomnia, weight gain, nasopharyngitis, 
and headache. While prolactin levels were increased, there was 
a low incidence of prolactin-related adverse events.72
In a post hoc study to evaluate the time to relapse follow-
ing treatment discontinuation with oral paliperidone, PP-1M 
and PP-3M data were drawn from three similarly designed 
relapse prevention, placebo-controlled RCTs (n=449). Median 
(95% CI) days to relapse were 58 days (42–114 days) for 
oral paliperidone, 172 days (134–222 days) for PP-1M, and 
395 days (274 days–not reached) for PP-3M (P0.0001).73 
The delayed time to relapse for the LAI PP formulations, 
particularly PP-3M, may be important in clinical practice 
where treatment gaps frequently occur (Table 4).
Discussion and conclusion
Taken together, the abovementioned studies suggest that PP 
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with risperidone. The tolerability profile of PP is similar 
to that of risperidone, with the most important side effects 
being prolactin elevation, weight gain, and extrapyramidal 
symptoms. Particularly in the early stages of illness, these 
side effects may be a significant barrier to effective treatment. 
Prolactin-related sexual dysfunction may be particularly rel-
evant to younger people, and so too excessive weight gain.
Compared with RLAI, PP offers advantages of not requir-
ing refrigeration or reconstitution prior to administration, or 
special needle kits.72 Additional advantages of PP include the 
following: First, there is a wealth of research data and clinical 
experience for both risperidone and paliperidone, so that the 
efficacy, safety, and tolerability profile of the compound is 
well known. Second, the availability of different formulations 
(PP-1M, PP-3M, and perhaps even longer-acting formula-
tions in future) provides clinicians and patients with a variety 
of treatment options. A longer interval between injections 
may be important when aiming for recovery, where patient 
autonomy and independent living are key considerations. 
Third, injections may be given in either the deltoid or gluteal 
muscles, which may be of importance to some patients. 
Finally, the PP-1M dose-initiation procedure provides rapid 
onset of action, thereby circumventing the need for oral 
supplementation and enabling its use in acute settings. The 
importance of adhering to the recommended initiation dosing 
regimen needs to be emphasized. Earlier studies suggested 
that using a lower initial dose may compromise the early 
treatment response.32 Subsequent carefully conducted clin-
ical trials and pharmacokinetic data confirmed the importance 
of the initial loading doses. In conclusion, PP is an important 
treatment option available to patients with schizophrenia and 
related illness, although cost considerations limit its use in 
resource-constrained environments.
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